Cent Eur J Public Health 2024, 32(Suppl):S4-7 | DOI: 10.21101/cejph.a7886

Chronic diseases and spondylodiscitis

Róbert Čellár1, Erik Dorko2, Kvetoslava Rimárová2, Dávid Sokol1, Ahmad Gharaibeh1, István Mitró1, Rastislav Šepitka1, Viliam Knap3
1 Department of Orthopaedics and Traumatology of Locomotory Apparatus, Faculty of Medicine, Pavol Jozef Šafárik University and Louis Pasteur University Hospital in Košice, Košice, Slovak Republic
2 Department of Public Health and Hygiene, Faculty of Medicine, Pavol Jozef Šafárik University in Košice, Košice, Slovak Republic
3 Department of Physiatry, Balneology, and Medical Rehabilitation, Faculty of Medicine, Pavol Jozef Šafárik University in Košice, Košice, Slovak Republic

Objective: Our research was focused to find a relation between the occurrence of spondylodiscitis and occurrence of chronic diseases. We were trying to discover some new risk factors and relations between chronic disorders in our research group. This analysis was also focused to detect factors that prolong the hospitalization of patients and worsen their prognosis.

Methods: A study was carried out involving patients with spondylodiscitis treated between 2013 and 2022. A statistical analysis expressed by several coefficients was calculated in software IBM SPSS 21.

Results: The study group comprised 32 (53.3%) females and 28 (46.7%) males. During the period the overall incidence of spondylodiscitis was increasing (except the year 2020 where only 2 patients were treated) with a peak in 2019. The average age of patients was 69.3 (±12.3) years, and the highest incidence was in the age group 60-69 years (n = 19, 31.7%). The most impacted vertebral region was lumbar (n = 29, 48.3%). The most prevalent associated comorbidity was some cardiovascular disorder (n = 39, 65%) followed by diabetes mellitus (DM) (n = 23, 38.3%). Genitourinary system was the most common source of primary infection (n = 22, 36.7%). Average length of stay was 34.3 (±14.5) days and surgery prolonged hospitalization period. Mortality rate was 1.7%.

Conclusion: The results of our study are confirmed by the data of other European and non-European studies. We confirmed diabetes mellitus and hypertension as the most common non-infectious risk factors of spondylodiscitis and the presence of pathogens in genitourinary system as the most frequent source of primary infection.

Keywords: spondylodiscitis, chronic diseases, risk factors, length of stay

Received: May 23, 2023; Revised: March 1, 2024; Accepted: March 1, 2024; Published: December 31, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Čellár R, Dorko E, Rimárová K, Sokol D, Gharaibeh A, Mitró I, et al.. Chronic diseases and spondylodiscitis. Cent Eur J Public Health. 2024;32(Supplement):4-7. doi: 10.21101/cejph.a7886. PubMed PMID: 39832141.
Download citation

References

  1. Berbari EF, Kanj SS, Kowalski TJ, Darouiche RO, Widmer AF, Schmitt SK, et al. 2015 Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. Clin Infect Dis. 2015;61(6):e26-46. Go to original source... Go to PubMed...
  2. Kramer A, Thavarajasingam SG, Neuhoff J. Epidemiological trends of pyogenic spondylodiscitis in Germany: an EANS Spine Section Study. Sci Rep. 2023;13:20225. doi: 10.1038/s41598-023-47341-z. Go to original source... Go to PubMed...
  3. Conan Y, Laurent E, Belin Y, Lacasse M, Amelot A, Mulleman D, et al. Large increase of vertebral osteomyelitis in France: a 2010-2019 cross-sectional study. Epidemiol Infect. 2021;149:e227. doi: 10.1017/S0950268821002181. Go to original source... Go to PubMed...
  4. Schoof B, Stangenberg M, Mende KC, Thiesen DM, Ntalos D, Dreimann M. Obesity in spontaneous spondylodiscitis: a relevant risk factor for severe disease courses. Sci Rep. 2020;10:21919. doi: 10.1038/s41598-020-79012-8. Go to original source... Go to PubMed...
  5. Danda GJN, Castro CN. Pyogenic Spondylodiscitis: risk factors for therapeutic failure and recurrence. Coluna. 2023;22(2):e268880. doi: 10.1590/S1808-185120232202268880. Go to original source...
  6. Joerger AK, Albrecht C, Lange N, Meyer B, Wostrack M. In-Hospital Mortality from Spondylodiscitis: Insights from a Single-Center Retrospective Study. J Clin Med. 2023; 12(23):7228. doi: 10.3390/jcm12237228. Go to original source... Go to PubMed...
  7. Skaf GS, Domloj NT, Fehlings MG, Bouclaous CH, Sabbagh AS, Kanafani ZA, et al. Pyogenic spondylodiscitis: an overview. J Infect Public Health. 2010;3(1):5-16. Go to original source... Go to PubMed...
  8. Lang S, Walter N, Schindler M, Baertl S, Szymski D, Loibl M, et al. The epidemiology of spondylodiscitis in Germany: a descriptive report of incidence rates, pathogens, in-hospital mortality, and hospital stays between 2010 and 2020. J Clin Med. 2023;12(10):3373. doi: 10.3390/jcm12103373. Go to original source... Go to PubMed...
  9. Akiyama T, Chikuda H, Yasunaga H, Horiguchi H, Fushimi K, Saita K. Incidence and risk factors for mortality of vertebral osteomyelitis: a retrospective analysis using the Japanese diagnosis procedure combination database. BMJ Open. 2013;3(3):e002412. doi: 10.1136/bmjopen-2012-002412. Go to original source... Go to PubMed...
  10. Thavarajasingam SG, Subbiah Ponniah H, Philipps R, Neuhoff J, Kramer A, Demetriades AK, et al. Increasing incidence of spondylodiscitis in England: an analysis of the national health service (NHS) hospital episode statistics from 2012 to 2021. Brain Spine. 2023;3:101733. doi: 10.1016/j.bas.2023.101733. Go to original source... Go to PubMed...
  11. Kiňová S, Koreň M. [Thyropathies in the general practitioner's clinic]. Via practica. 2016;13(6):252-5. Slovak.
  12. Taylor PN, Albrecht D, Scholz A, Gutierrez-Buey G, Lazarus JH, Dayan CM, et al. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol. 2018;14(5):301-16. Go to original source... Go to PubMed...
  13. Lestin-Bernstein F, Tietke M, Briedigkeit L, Heese O. Diagnostics and antibiotic therapy for spondylodiscitis. J Med Microbiol. 2018;67(6):757-68. Go to original source... Go to PubMed...
  14. Chang WS, Ho MW, Lin PC, Ho CM, Chou CH, Lu MC, et al. Clinical characteristics, treatments, and outcomes of hematogenous pyogenic vertebral osteomyelitis, 12-year experience from a tertiary hospital in central Taiwan. J Microbiol Immunol Infect. 2018;51(2):235-42. Go to original source... Go to PubMed...
  15. Widdrington JD, Emmerson I, Cullinan M, Narayanan M, Klejnow E, Watson A, et al. Pyogenic spondylodiscitis: risk factors for adverse clinical outcome in routine clinical practice. Med Sci (Basel). 2018;6(4):96-102. Go to original source... Go to PubMed...
  16. Stangenberg M, Mende KC, Mohme M, Krätzig T, Viezens L, Both A, et al. Influence of microbiological diagnosis on the clinical course of spondylodiscitis. Infection. 2021;49(5):1017-27. Go to original source... Go to PubMed...
  17. Kim NJ. Microbiologic diagnosis of pyogenic spondylitis. Infect Chemother. 2021;53(2):238-46. Go to original source... Go to PubMed...
  18. Rose L, Iossifidis A. Diagnosis and treatment of spondylodiscitis: current concepts. Int J Orthop. 2022;9(4):1670-5.
  19. Hohenberger C, Schmidt NO, Doenitz C, Ullrich OW, Schebesch KM. Infectious spondylodiscitis of the lumbar spine: conservative antibiotic therapy vs. antibiotic therapy with surgery, and the time of surgery. Neurol India. 2022;70(1):155-9. Go to original source... Go to PubMed...
  20. Thavarajasingam SG, Vemulapalli KV, Vishnu KS, Ponniah HS, Vogel AS, Vardanyan R, et al. Conservative versus early surgical treatment in the management of pyogenic spondylodiscitis: a systematic review and meta-analysis. Sci Rep. 2023;13(1):15647. doi: 10.1038/s41598-023-41381-1. Go to original source... Go to PubMed...